Introduction
Lyme borreliosis is reported in widely separated regions of North America and Eurasia where Ixodes pacificus, I. persulcatus, I. ricinus or I. scapularis ticks occur. In the USA, Lyme borreliosis is caused by Borrelia burgdorferi sensu stricto and is the most frequently reported vector-borne infection [1] . In some areas of Europe, strains of this bacterium co-exist with B. garinii and B. afzelii [2] [3] [4] in nature. These closely related organisms are associated with distinct clinical manifestations of disease [2, 3] .
Diagnosis of Lyme borreliosis is based on clinical and laboratory findings. Erythema migrans (EM) is a useful clinical feature for diagnosis. However, in the absence of EM the clinical picture can be unclear and, consequently, clinicians rely on antibody detection analyses to determine the cause of illness. A two-step process, which usually includes enzyme-linked immunosorbent assays (ELISAs) followed by Western blot analysis, is used in the USA [5] and Europe. Difficulties associated with the sensitivities and specificities of these assays, inter-laboratory discrepancies due to nonstandardised tests, complications due to co-migration of proteins of similar molecular masses in blots, and higher costs of performing immunoblot analyses are important limitations. Moreover, the use of whole-cell, sonicated antigens of B. burgdorferi in ELISAs can yield false positive results [6, 7] due to cross-reactivity of antibodies to treponemes or other bacteria.
Human granulocytic ehrlichiosis (HGE) occurs in tick-
infested areas where Lyme borreliosis is reported. When EM is absent, clinical manifestations of HGE, such as headache, fever and fatigue, can be confused with those of Lyme borreliosis and other diseases. Laboratory analyses to identify disorders associated with abnormal blood cell counts (i.e., thrombocytopenia or leukopenia) and to determine concentrations of serum hepatic transaminase can help separate HGE from Lyme borreliosis, but detection of antibodies to specific recombinant antigens also can be used to diagnose HGE infections.
In efforts to improve the utility of immunodiagnostic tests for Lyme borreliosis, numerous recombinant antigens of B. burgdorferi have been produced and evaluated [8] [9] [10] [11] [12] [13] . ELISAs with outer-surface protein (Osp) C, OspF, protein (p) 35 and p37 yield highly specific results but may exhibit low sensitivity [9, 12] . Recent studies have demonstrated that the surfaceexposed lipoprotein VlsE [14] may serve as an effective antigen for immunodiagnosis of Lyme borreliosis. During experimental infection of mice, rapid recombination in the central cassette region of the vlsE gene results in substantial sequence changes with six variable regions (VRs 1-6) but not within invariant regions (IRs 1-6) [14] . Surprisingly, VlsE was found to be highly antigenic despite these sequence changes. Incorporation of full-length, recombinant VlsE or a synthetic peptide corresponding to IR6 in polyvalent or class-specific ELISAs resulted in a high degree of sensitivity and specificity in analyses of sera from North American and European Lyme borreliosis patients or from experimentally infected animals [10, 11, 13] . Western blot methods confirmed ELISA results [11] . The purpose of the present study was to test a full-length recombinant VlsE protein in class-specific ELISAs with a panel of North American human sera, with a focus on samples obtained during early Lyme borreliosis, and to compare these results with those obtained by ELISAs utilising other recombinant proteins or whole-cell B. burgdorferi antigens.
Materials and methods

Study groups
Serum samples, representing eight study groups, were obtained from archived collections at the Connecticut Agricultural Experiment Station. The first group consisted of 20 serum samples from 20 patients who had physician-diagnosed EM and whose sera contained antibodies against whole-cell B. burgdorferi sensu stricto (strain 2591), as determined previously by polyvalent and class-specific ELISAs [9] . All persons resided in tick-infested areas of Connecticut, USA. Blood specimens were obtained 1-6 weeks after onset of illness and before the initiation of antibiotic therapy. Group two contained 44 serum samples from 44 Connecticut patients who had been diagnosed with HGE, had no detectable antibodies to Anaplasma phagocytophila (formerly Ehrlichia phagocytophila [15] ) but had immunoglobulins that reacted with whole-cell B. burgdorferi. The third group included 11 sera from 11 HGE patients whose infections were confirmed by positive cultures, DNA analysis, Western blot analysis with whole-cell antigens of the NCH-1 strain, or by ELISAs that utilised a highly specific p44 HGE recombinant antigen. The HGE patient sera in this group showed no reactivity with B. burgdorferi whole-cell antigens by an ELISA [9] . All HGE patients in the second and third groups had thrombocytopenia or leukopenia; serum samples were obtained 3-5 weeks after onset of illness. To further assess specificities, human sera were also selected from frozen collections representing the following study groups: syphilis (24 serum samples), louse-borne relapsing fever (11) , acute necrotising ulcerative gingivitis or periodontitis (6) , and rheumatoid arthritis (7) . Clinical findings, sources of sera and serological reactivities for the specimens in these four groups have been reported previously [6, 9] . Syphilitic sera had high antibody titres (>1024) to Treponema pallidum in a standardised fluorescent-treponemal antibody-absorption test [16] . Louse-borne relapsing fever sera were from Addis Ababa, Ethiopia; diagnoses were based on clinical manifestations, positive blood smears for B. recurrentis, or the presence of homologous antibodies in immobilisation or microscopic agglutination tests [6] . The final group consisted of 28 serum samples from healthy subjects (i.e., normal controls) who lived in urban or suburban areas of Connecticut where tick-associated diseases are uncommon and who had no histories of Lyme borreliosis or HGE infections. All sera were stored at À608C before analysis at the Connecticut Agricultural Experiment Station and were promptly refrozen after analysis to prevent loss of antibodies associated with the freezing and thawing processes. Informed consent was obtained from patients, and research protocols were approved by Yale University and the State of Connecticut Health Department.
Test antigens
A recombinant form of VlsE (VlsE1-His), consisting of an N-terminal polyhistidine tag followed by VlsE1 without the native signal sequence, was produced and purified as described previously [11] . For comparative analyses, whole-cell B. burgdorferi strain 2591 from Connecticut, USA, and the recombinant antigens p22, p35, p37, p39, p41-G, OspA, OspB, OspC, OspE and OspF were tested separately in class-specific ELISAs as reported previously [9] . These recombinant antigens were cloned, expressed and purified as glutathione Stransferase (GST) fusion proteins in Escherichia coli. The newly acquired p35 (47-kDa fibronectin-binding protein) GST fusion recombinant antigen was prepared as described previously [17] . Affinity-purified GST was used as a negative control. 
ELISA
IgM and IgG antibodies were detected by solid-phase, non-competitive class-specific ELISAs [9] . Briefly, the wells of flat-bottomed, polystyrene plates (Nunc A/S, Roskilde, Denmark) were coated with individual antigen preparations as described previously [9] ; the optimal concentrations of p35 and VlsE1-His antigens were 5 ìg=ml and 1 ìg=ml, respectively, as determined by chequerboard titrations (data not shown). Wells incubated with phosphate-buffered saline (PBS) without antigen were also used for each serum sample as a negative control. All serum samples were initially diluted in PBSS (pH 7.2) to 1 in 160, 1 in 320 and 1 in 640. If positive, sera were tested at higher dilutions as needed to establish end-point concentrations. In tests for IgM antibody, a 1 in 8000 dilution of affinity-purified horseradish peroxidase-labelled goat anti-human antibody (ì-chain specific) produced by Kirkegaard & Perry Laboratories (Gaithersburg, MD, USA) was used.
In analyses for IgG antibodies, the conjugate was a 1 in 10 000 dilution of ª-chain specific, affinity-purified horseradish peroxidase-labelled goat anti-human IgG antibodies (Kirkegaard & Perry Laboratories). Details of blocking, incubation, washing procedures, the substrate used, and the measurement of absorbance values have been reported elsewhere [9, 18, 19] .
Net absorbance values are differences in optical density (OD) readings with or without antigen for each serum dilution. Reactivity cut-off values for each serum dilution were established by statistical analyses as the mean plus 3 SD of the net absorbance values obtained after testing a panel of sera from healthy subjects. In general, the cut-off values obtained at a serum dilution of 1 in 640 were used for defining reactivity at higher serum dilutions. The titration end-point for each serum dilution was defined as the highest dilution at which the net OD was greater than the cut-off values. The cut-off values for whole-cell or all recombinant antigens except p35 and VlsE were reported previously [9, 17] . To determine cut-off values for each assay with p35 and VlsE antigens, respective panels of 24 and 44 human sera (obtained from persons who had no history of tick-borne infections and who lived in urban or suburban areas in Connecticut) were used. These sera had been analysed earlier [9] 
Statistical analyses
A statistical software programme (Sigmastat; SPSS, Chicago, IL, USA) was used to calculate z statistics to determine significant differences in proportions of positive results. The Yates correction was applied in all tests.
Results
IgM antibodies
In all, 151 serum samples, representing eight study groups, were tested for IgM antibodies to whole-cell B. burgdorferi and 11 recombinant antigens (Table 1) . EM, erythema migrans; HGE, human granulocytic ehrlichiosis; LB, Lyme borreliosis serologically confirmed; Syphilis, secondary or latent; LBRF, louse-borne relapsing fever; RA, rheumatoid arthritis; Normal, healthy subjects with no history of tick-borne infections; ND, not done (antigens unavailable). Ã All serum group-antigen combinations listed were analysed independently as a part of this study. Some sera reacted with more than one antigen. In some instances, re-analysis of certain serum-antigen combinations resulted in data that were identical to previously published results [9] .
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Seroprevalence of >25% was used as an arbitrary guideline for identifying recombinant antigens that may be useful in Lyme borreliosis diagnosis. Analysis of IgM antibodies for patients with EM indicated seroprevalences of >25% when the following recombinant antigens were used: OspC (55%), p41-G (55%), p37 (45%), VlsE (40%), OspE (35%) and OspF (25%). Statistical examination of the IgM results obtained for the pairings of VlsE and OspF (z ¼ 0.675, p ¼ 0.500) and VlsE and OspC (z ¼ 0.633, p ¼ 0.527) showed that these seropositivity rates were not significantly different. ELISA results for sera from persons diagnosed with HGE and Lyme borreliosis but lacking antibodies to A. phagocytophila had a similar pattern of reactivity. In this group, the highest proportions of sera with IgM antibody were recorded for OspC (52%), p41-G (52%), p22 (52%), p37 (46%) and p39 (43%). In contrast, IgM antibodies were detected in relatively few sera from patients diagnosed with HGE only (group 3), with patient sera having a seroprevalence .25% for only two antigens (p37 and p22). These results were generally considered to be possible false positives because there were no reactions when sera were tested with whole-cell B. burgdorferi. However, one serum sample in this group reacted with recombinant p22, p41-G, OspF and VlsE antigens, suggesting that the patient may have had Lyme borreliosis before or at the time the blood sample was obtained.
False positive reactions were recorded for sera from patients with conditions unrelated to tick-borne infections when p22, p37, p39, p41G, OspC, OspE or OspF were used as antigens (Table 1 ). In addition, eight normal sera reacted to one or more of the following antigens: p22, p35, p39, p41-G or OspC. Assays with VlsE, OspA and OspB antigens were negative when sera from healthy subjects or patients who had syphilis, oral infections and rheumatoid arthritis were tested.
IgG antibodies
In analyses of IgG antibodies ( False positive IgG antibody reactions were recorded when sera in various control groups were tested ( Table  2 ). There were reactions with p22, p35, p37, p39, p41-G, OspC and OspF antigens when sera from patients who had syphilis, louse-borne relapsing fever, oral infections or rheumatoid arthritis were analysed. Furthermore, 14 normal sera reacted with p22, p39, p41-G, OspC and OspF. Only one serum sample from the nonLyme borreliosis patients (i.e., louse-borne relapsing fever) reacted weakly (titre of 320) when VlsE antigen was used in assays for IgG antibodies. Thus, tests with VlsE antigen had higher specificity than those with whole-cell B. burgdorferi or other recombinant antigens except OspB and OspE. However, the tests utilising the latter two antigens had low sensitivities. (Table 3) . When 76 sera from non-Lyme borreliosis or HGE patients and healthy subjects were tested, the proportions of false positive reactions for all three recombinant proteins were 13% and 18% for IgM and IgG antibodies, respectively. Nearly all these reactions were due to reactivity with either OspC or OspF. There were also OspC, OspF and VlsE reactivities with a serum sample from one HGE patient where past or present Lyme borreliosis was suspected, as noted above.
Comparison of recombinant antigen reactivities
Analysis of antibody titres
Antibody concentrations were determined for the sera from EM patients with each of the antigens examined in this study ( Table 4 ). The geometric means and ranges of antibody titres were highly variable among samples and were greatly dependent on the antigens used. In analyses for IgM antibody, maximal antibody titres of >5120 were recorded for certain sera in assays utilising whole-cell, p22, p41-G, VlsE and OspC antigens. The geometric means for ELISA results with these antigens were also elevated. Maximal titration end-points for IgG antibodies were recorded in tests in which whole-cell, p39, p41-G and VlsE antigens were used in ELISAs; results for the VlsE antigen indicated the highest geometric mean titre (2061).
Because the assays with VlsE antigen appeared to be sensitive and specific, duplicate ELISAs with this reagent were conducted on separate days to determine if antibody titration end-points were reproducible. Seven sera from EM patients with a wide range of antibody titres (320-40 960) were selected for analysis. Titres for IgM antibodies varied by two-fold for six samples and by four-fold for one sample in duplicate tests. Reproducibility trials for IgG antibody concentrations indicated the same value for two samples, a two-fold variation for two samples and a four-fold difference for three sera. Results for an additional five normal sera remained negative in duplicate trials for both class-specific assays.
Discussion
In an attempt to increase the accuracy of Lyme borreliosis diagnosis, the sensitivities and specificities of 11 different B. burgdorferi recombinant antigens were examined by ELISA. Taking both the IgM and IgG antibody results into account, the VlsE antigen was most consistent in laboratory confirmation of Lyme borreliosis, compared with the other antigens tested. These results parallel those reported elsewhere showing high sensitivity and specificity of ELISAs with either full-length recombinant VlsE [11] or a peptide corresponding to IR6 of VlsE as antigen [14] . The seropositivity rate for EM patient sera in the present study was greater for IgG antibodies (80%) than for IgM antibody (40%) when VlsE antigen was used. The other antigens in the present study also showed variability in reactivity when testing for IgM and IgG antibodies, which is consistent with the dynamic nature of immune responses during the early stage of Lyme borreliosis infection. The sensitivity of ELISAs increases with time after onset of illness [10, 11] as antibody concentrations rise. Therefore, when initial Different patterns of reactivities to recombinant antigens were noted in tests for specificity. The use of highly specific recombinant antigens, such as p41-G, OspC and OspF, increases the specificity of ELISAs, as indicated in this and previous work [9] . However, the sensitivities of assays with these antigens can be low. In the current study, ELISAs with the VlsE antigen were highly sensitive and specific for Lyme borreliosis when testing for IgG antibodies. Although less specific than the VlsE antigen, antibody reactivities with p41-G, OspC and OspF, in conjunction with seroreactivity to VlsE, may also be useful diagnostically for identifying past or current B. burgdorferi infections. Furthermore, one serum sample from a patient clinically diagnosed with HGE and having no EM [20] exhibited a positive IgM antibody reaction to VlsE. In tick-infested areas of North America, Lyme borreliosis and HGE often coexist where I. pacificus and I. scapularis abound [21, 22] . Co-infections in man have been verified by culture methods [23] and suggested by the co-existence of antibodies to B. burgdorferi and A. phagocytophila in the same host [20, 24, 25] . The HGE patient in the present study had not been diagnosed previously with Lyme borreliosis, but there was reactivity of the patient's serum with p22, p41-G, OspF and VlsE antigens. With antibody presence to VlsE, in particular, we suspect that this reaction was specific for B. burgdorferi and that this individual had been exposed to different agents that cause Lyme borreliosis and HGE. However, it is unclear whether the patient had concurrent infections or if exposure to disease organisms occurred separately. Similar antibody reactions have been reported before when HGE was diagnosed, but sera contained antibodies to B. burgdorferi rather than to the HGE agent [20] . The use of VlsE antigen in ELISAs may help clarify seroprevalence of past or current B. burgdorferi infections in HGE patients and may facilitate the separation of natural B. burgdorferi infections from OspA vaccine-induced seroreactivity [10, 11] . Finally, one serum sample from a patient who had louse-borne relapsing fever cross-reacted with VlsE antigen in tests for IgG antibodies. However, this disease is rare in the USA and Europe and can be distinguished clinically from Lyme borreliosis. This cross-reactivity may be due to sequence similarity between variable large proteins expressed by relapsing fever organisms and VlsE [13] .
In Europe, B. burgdorferi, B. garinii and B. afzelii cause human infections [2] [3] [4] . Earlier studies indicated that a synthetic peptide based on the VlsE IR6 of B. garinii (strain Ip 90) has an epitope that frequently reacts with serum antibodies from Lyme borreliosis patients in the USA and Europe [10, 13] . It is possible that the invariable domains of the VlsE molecule may serve as a probe for universal serodiagnosis of human Lyme borreliosis. However, a recent study [26] showed that a 51 amino acid peptide corresponding to the Cterminal, invariable domain of VlsE is highly immunogenic but does not react consistently with sera from European Lyme borreliosis patients. The low reactivity of sera from some patients may be due to heterogeneity in the C-terminal sequence of VlsE [26] . Further analysis of VlsE heterogeneity and reactivity with human Lyme borreliosis sera from broad geographical regions is needed.
Although an overall seroprevalence of 80% was obtained with VlsE in this study, IgM antibody was not detected in some serum samples representing early B. burgdorferi infections regardless of which recombinant antigens were used. Humoral responses vary in infected persons, and IgM antibody may remain at very low, undetectable concentrations. Analyses of sequential serum samples can help to improve laboratory diagnosis, as concentrations of IgG antibodies rise with expansion in immune responses. While VlsE appears to be an excellent candidate as a single antigen in ELISA to test more specifically for Lyme borreliosis antibodies, a mixture of immunodominant antigens -such as VlsE with OspC or OspF -may alternatively enhance the sensitivity of class-specific or polyvalent ELISAs used in initial screening of sera before immunoblotting. To improve assay efficiency and reduce potential interference problems and loss of sensitivity associated with excessive amounts of GST in microplate wells, genes encoding VlsE and selected additional recombinant antigens could be fused to form a composite antigen [27] rather than mixing separate recombinant antigens in cocktail form.
